University of Basel identifies levetiracetam's potential in diffuse midline glioma

University of Basel research suggests levetiracetam may target diffuse midline glioma cells

University of Basel researchers identified that levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma—a rare brain cancer with median survival of 12 months. This preclinical finding offers potential for affordable treatment where current options are limited. The work advances security by improving access to targeted therapies for this condition.

While levetiracetam is a low-cost medication already used for seizures, this research shows it could extend survival for diffuse midline glioma patients by addressing the cancer’s molecular pathways. However, this remains early-stage work: no human trials have been conducted yet, and the treatment’s real-world impact depends on future clinical validation. The source material provides no details on trial stages or patient numbers, so the full implications sit with the original research team.

Source: Nature Medicine